AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

Phase 1 Completed 128 enrolled AstraZeneca

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this Phase 1b, multi-centre, dose escalation study is to find the maximum tolerated dose (MTD) of AZD1775 combined with olaparib in patients with refractory solid tumours

Timeline

Start: 2015-08-06
Primary completion: 2019-04-25
Completion: 2019-10-16

Publications

Hamilton EP, Falchook GS, Wang JS, Fu S, Oza AM, Imedio ER, Kumar S, Ottesen L, Mugundu GM, de Bruin EC, O'Connor MJ, Jones SF, Spigel DR, Li BT. Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial. Target Oncol. 2024 Nov;19(6):879-892. doi: 10.1007/s11523-024-01102-8. Epub 2024 Nov 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adavosertib	Small molecule	175 mg	Oral
Subject	Adavosertib	Small molecule	200 mg	Oral
Subject	Olaparib	Small molecule	200 mg	Oral

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

Summary

Timeline

Publications

Drugs

Indications